Germie M. Van Den Dobbelsteen

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

Validation of electrochemiluminescent (ECL)-based immunoassay to determine the levels of antibodies against Escherichia coli O-lipopolysaccharide antigens.

Validation of electrochemiluminescent (ECL)-based immunoassay to determine the levels of antibodies against Escherichia coli O-lipopolysaccharide antigens.

Journal: Microbiology spectrum
Published: September 08, 2026

Development and validation of a high-throughput agglutination assay for O-serogrouping clinical Escherichia coli isolates.

Development and validation of a high-throughput agglutination assay for O-serogrouping clinical Escherichia coli isolates.

Journal: Microbiology spectrum
Published: August 21, 2026

Establishment and optimization of an E. coli urinary tract infection model in Göttingen minipigs with strain recovery and characterization.

Establishment and optimization of an E. coli urinary tract infection model in Göttingen minipigs with strain recovery and characterization.

Journal: Frontiers in immunology
Published: March 30, 2026

The Bacterial Swiss Army Knife: ExPEC Utilizes Multiple Resistance Mechanisms to Counteract Host Immune Responses.

The Bacterial Swiss Army Knife: ExPEC Utilizes Multiple Resistance Mechanisms to Counteract Host Immune Responses.

Journal: Vaccines
Published: November 27, 2025

Harnessing pro-inflammatory and immunopathologic immune responses in urinary tract infections for vaccine development: it's all about a balance.

Harnessing pro-inflammatory and immunopathologic immune responses in urinary tract infections for vaccine development: it's all about a balance.

Journal: Frontiers in immunology
Published: November 24, 2025

A SpA+LukAB vaccine targeting Staphylococcus aureus evasion factors restricts infection in two minipig infection models.

A SpA+LukAB vaccine targeting Staphylococcus aureus evasion factors restricts infection in two minipig infection models.

Journal: NPJ vaccines
Published: November 13, 2024

A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI.

A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI.

Journal: NPJ vaccines
Published: October 23, 2023

Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.

Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.

Journal: Open forum infectious diseases
Published: April 05, 2023

Colonization with Escherichia coli ST131-H30R (H30R) Corresponds with Increased Serum Anti-O25 IgG Levels and Decreased TNFα and IL-10 Responsiveness to H30R.

Colonization with Escherichia coli ST131-H30R (H30R) Corresponds with Increased Serum Anti-O25 IgG Levels and Decreased TNFα and IL-10 Responsiveness to H30R.

Journal: Pathogens (Basel, Switzerland)
Published: February 28, 2023

Vaccination With Detoxified Leukocidin AB Reduces Bacterial Load in a Staphylococcus aureus Minipig Deep Surgical Wound Infection Model.

Vaccination With Detoxified Leukocidin AB Reduces Bacterial Load in a Staphylococcus aureus Minipig Deep Surgical Wound Infection Model.

Journal: The Journal of infectious diseases
Published: February 10, 2021

Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial.

Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial.

Journal: The Lancet. Infectious diseases
Published: July 30, 2018

Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.

Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.

Journal: Vaccine
Published: July 08, 2018
Showing 1-12 of 31

Last Updated: 09/26/2026